Cystic Fibrosis
📧 Sign up to get email alerts when something new happens for Cystic Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
Terminated clinical trial update examining the epidemiology and clinical characteristics of non-tuberculous mycobacterial infections in cyst…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation
A clinical trial aims to establish a primary epididymal cell model from epididymal samples to study CFTR gene regulation, relevant to cystic…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years [EARLY_Phase 1]
Early-phase trial update for inhaled BMD003 (CFTR mRNA) in Chinese cystic fibrosis patients aged 12 years and older; the study is not yet re…
-
EMA approval · 2026-03-19EMA Authorised: Kaftrio (ivacaftor;tezacaftor;elexacaftor) — Vertex Pharmaceuticals (Ireland) Limited
The EMA authorised Kaftrio, a fixed-dose triple combination of ivacaftor, tezacaftor and elexacaftor, for cystic fibrosis, with orphan desig…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
This ClinicalTrials.gov update notes a recruiting study aimed at identifying causes and risk factors of pulmonary exacerbations in cystic fi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Assessing Tenapanor as a Treatment of CF-related Constipation. [Phase 3]
Phase 3 study evaluating tenapanor for constipation associated with cystic fibrosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis [NA]
A completed clinical trial assessed the effect of the Simeox bronchial drainage device on respiratory function and symptoms in adults with c…
-
FDA approval · 2026-03-17FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
FDA approved a supplemental application for KALYDECO (ivacaftor) submitted by Vertex Pharmaceuticals Incorporated. The action updates the pr…
-
FDA approval · 2026-03-17FDA Approved: TRIKAFTA — Supplemental Application (Vertex Pharmaceuticals Incorporated)
FDA approves a supplemental application for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) submitted by Vertex Pharmaceuticals Incorporated.
-
FDA approval · 2026-03-17FDA Approved: TRIKAFTA — Supplemental Application (Vertex Pharmaceuticals Incorporated)
FDA approved a supplemental application for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) from Vertex Pharmaceuticals Incorporated. The approv…
-
FDA approval · 2026-03-17FDA Approved: ALYFTREK — Supplemental Application (Vertex Pharmaceuticals Incorporated)
FDA approved a supplemental application for ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR) from Vertex Pharmaceuticals Incorporated.
-
FDA approval · 2026-03-17FDA Approved: ORKAMBI — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved a supplemental application for ORKAMBI (lumacaftor/ivacaftor) by Vertex Pharmaceuticals.
-
FDA approval · 2026-03-17FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approves a supplemental application for KALYDECO (ivacaftor) submitted by Vertex Pharmaceuticals Incorporated.
-
FDA approval · 2026-03-17FDA Approved: SYMDEKO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved a supplemental application for Symdeko (tezacaftor and ivacaftor) submitted by Vertex Pharmaceuticals.
-
FDA approval · 2026-03-17FDA Approved: ORKAMBI — Supplemental Application (Vertex Pharmaceuticals Incorporated)
FDA approved a supplemental application for ORKAMBI, the lumacaftor/ivacaftor combination manufactured by Vertex Pharmaceuticals Incorporate…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis [NA]
A clinical trial is recruiting to evaluate a personalized mobile health platform intended to promote physical activity in adolescents and yo…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
Clinical trial update focusing on strength and muscle-related outcomes from nutrition interventions and their relation to lung function in c…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis [Phase 2]
A Phase 2 trial evaluating the safety, tolerability, and pharmacokinetics of Brensocatib tablets in adults with cystic fibrosis has complete…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: 4D-710 in Adult Patients With Cystic Fibrosis [Phase 2]
Phase 2 clinical trial of 4D-710 for cystic fibrosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®. [NA]
A completed clinical trial update validating a respiratory epithelial functional assay to predict the clinical efficacy of Orkambi in people…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Streamlined Treatment of Pulmonary Exacerbations in Pediatrics [NA]
The study 'Streamlined Treatment of Pulmonary Exacerbations in Pediatrics' is a recruiting clinical trial sponsored by the University of Was…
-
EMA approval · 2026-03-09EMA Authorised: Cayston (aztreonam lysine) — Gilead Sciences Ireland UC
EMA authorised Cayston (aztreonam lysine) from Gilead Sciences Ireland UC for use in cystic fibrosis and related respiratory tract infection…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure .
This clinical trial evaluates whether MRI can detect changes in airway structure in people with cystic fibrosis.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Phase 2 Study to Assess the Safety and Efficacy of ANG003 [Phase 2]
Phase 2 clinical trial to evaluate the safety and efficacy of ANG003 for exocrine pancreatic insufficiency and cystic fibrosis. The study st…
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older [Phase 3]
Phase 3 long-term safety and efficacy update of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients aged 2 years and older; the stu…